Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Neoplasms 2Liver Neoplasms 2Liver Diseases 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Rheumatic Diseases 1Primary Graft Dysfunction 1Liver Failure, Acute 1Liver Failure 1Head and Neck Neoplasms 1HIV Infections 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Oxaliplatin 32Fluorouracil 24Gemcitabine 23Leucovorin 19Docetaxel 19pembrolizumab 17Capecitabine 15Radiotherapy 14Irinotecan 13Cisplatin 11Bevacizumab 11Nivolumab 8130-nm albumin-bound paclitaxel 8Trastuzumab 7Erlotinib Hydrochloride 7Cyclophosphamide 7Albumin-Bound Paclitaxel 7Radiosurgery 6Paclitaxel 6Taxes 5S 1 (combination) 5Metformin 5Carboplatin 5Blood Specimen Collection 5Sunitinib 4Sorafenib 4Pemetrexed 4Esophagectomy 4Chemoradiotherapy 4Cetuximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma × halofantrine × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡